Vertex Pharmaceuticals Files 8-K on Financials
Ticker: VRTX · Form: 8-K · Filed: Aug 1, 2024 · CIK: 875320
Sentiment: neutral
Topics: financial-reporting, 8-k
Related Tickers: VRTX
TL;DR
VRTX filed an 8-K on Aug 1st detailing financial results and exhibits.
AI Summary
Vertex Pharmaceuticals Incorporated filed an 8-K on August 1, 2024, reporting on its results of operations and financial condition, as well as financial statements and exhibits. The filing is a current report under the Securities Exchange Act of 1934.
Why It Matters
This filing provides crucial updates on Vertex Pharmaceuticals' financial performance and condition, which can impact investor decisions and stock valuation.
Risk Assessment
Risk Level: low — This is a routine financial filing and does not indicate any unusual risks.
Key Players & Entities
- Vertex Pharmaceuticals Incorporated (company) — Registrant
- Massachusetts (location) — State of incorporation
- 04-3039129 (other) — I.R.S. Employer Identification No.
- 50 Northern Avenue Boston (address) — Principal executive offices
- 02210 (other) — Zip code
- 617-341-6100 (phone_number) — Registrant's telephone number
- August 1, 2024 (date) — Date of earliest event reported
FAQ
What is the primary purpose of this Form 8-K filing?
The primary purpose of this Form 8-K filing is to report on Vertex Pharmaceuticals Incorporated's results of operations and financial condition, as well as to provide financial statements and exhibits.
When was this Form 8-K filed?
This Form 8-K was filed on August 1, 2024.
Under which section of the Securities Exchange Act is this report filed?
This report is filed pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934.
What is Vertex Pharmaceuticals Incorporated's state of incorporation?
Vertex Pharmaceuticals Incorporated's state of incorporation is Massachusetts.
What is the address of Vertex Pharmaceuticals Incorporated's principal executive offices?
The address of Vertex Pharmaceuticals Incorporated's principal executive offices is 50 Northern Avenue, Boston, Massachusetts 02210.
Filing Stats: 518 words · 2 min read · ~2 pages · Grade level 10.9 · Accepted 2024-08-01 16:05:43
Key Financial Figures
- $0.01 — nge on which registered Common Stock, $0.01 Par Value Per Share VRTX The Nasdaq G
Filing Documents
- vrtx-20240801.htm (8-K) — 25KB
- ex-991_q22024.htm (EX-99.1) — 239KB
- 0000875320-24-000193.txt ( ) — 412KB
- vrtx-20240801.xsd (EX-101.SCH) — 2KB
- vrtx-20240801_lab.xml (EX-101.LAB) — 21KB
- vrtx-20240801_pre.xml (EX-101.PRE) — 12KB
- vrtx-20240801_htm.xml (XML) — 3KB
02. Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition. On August 1, 2024, we issued a press release in which we reported our consolidated financial results for the three and six months ended June 30, 2024. A copy of that press release is attached to this Current Report on Form 8-K as Exhibit 99.1 and is incorporated herein by reference. The information set forth in Exhibit 99.1 shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit Description of Document 99.1 Press Release Dated August 1, 2024 . 104 Cover Page Interactive Data File — the cover page XBRL tags are embedded within the Inline XBRL document.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. VERTEX PHARMACEUTICALS INCORPORATED (Registrant) Date: August 1, 2024 /s/ Jonathan Biller Jonathan Biller Executive Vice President, Chief Legal Officer